Laboratory Corporation of Ameri – Consensus Indicates Potential 34.3% Upside
Laboratory Corporation of Ameri with ticker code (LH) now have 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 320 and 265 and has a mean target at 303.69. Now with the previous closing price of 226.1 this indicates there is a potential upside of 34.3%. The 50 day MA is 244.59 and the 200 moving average now moves to 262.63. The company has a market cap of $20,967m. Visit the company website at: https:||www.labcorp.com [stock_market_widget type="chart" template="basic" color="green" assets="LH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $28,163m based on the market concensus. Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).
Laboratory Corporation of Ameri – Consensus Indicates Potential 34.3% Upside
Laboratory Corporation of Ameri with ticker code (LH) now have 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 320 and 265 and has a mean target at 303.69. Now with the previous closing price of 226.1 this indicates there is a potential upside of 34.3%. The 50 day MA is 244.59 and the 200 moving average now moves to 262.63. The company has a market cap of $20,967m. Visit the company website at: https:||www.labcorp.com [stock_market_widget type="chart" template="basic" color="green" assets="LH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $28,163m based on the market concensus. Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).